Vor Biopharma Stock Market Value
| VOR Stock | USD 12.98 0.20 1.56% |
| Symbol | Vor |
Can Biotechnology industry sustain growth momentum? Does Vor have expansion opportunities? Factors like these will boost the valuation of Vor Biopharma. If investors know Vor will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Vor Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Vor Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Vor Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Vor Biopharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Vor Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vor Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Vor Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.
Vor Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vor Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vor Biopharma.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Vor Biopharma on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Vor Biopharma or generate 0.0% return on investment in Vor Biopharma over 90 days. Vor Biopharma is related to or competes with Fate Therapeutics, Nkarta, Actuate Therapeutics, Alector, Forte Biosciences, PepGen, and Anixa Biosciences. Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients More
Vor Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vor Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vor Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.6 | |||
| Information Ratio | 0.0836 | |||
| Maximum Drawdown | 39.24 | |||
| Value At Risk | (10.24) | |||
| Potential Upside | 16.2 |
Vor Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vor Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vor Biopharma's standard deviation. In reality, there are many statistical measures that can use Vor Biopharma historical prices to predict the future Vor Biopharma's volatility.| Risk Adjusted Performance | 0.0806 | |||
| Jensen Alpha | 0.6912 | |||
| Total Risk Alpha | 0.2855 | |||
| Sortino Ratio | 0.1043 | |||
| Treynor Ratio | 0.7861 |
Vor Biopharma February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0806 | |||
| Market Risk Adjusted Performance | 0.7961 | |||
| Mean Deviation | 6.46 | |||
| Semi Deviation | 6.17 | |||
| Downside Deviation | 6.6 | |||
| Coefficient Of Variation | 1110.64 | |||
| Standard Deviation | 8.23 | |||
| Variance | 67.77 | |||
| Information Ratio | 0.0836 | |||
| Jensen Alpha | 0.6912 | |||
| Total Risk Alpha | 0.2855 | |||
| Sortino Ratio | 0.1043 | |||
| Treynor Ratio | 0.7861 | |||
| Maximum Drawdown | 39.24 | |||
| Value At Risk | (10.24) | |||
| Potential Upside | 16.2 | |||
| Downside Variance | 43.51 | |||
| Semi Variance | 38.05 | |||
| Expected Short fall | (7.56) | |||
| Skewness | 0.7767 | |||
| Kurtosis | 0.792 |
Vor Biopharma Backtested Returns
Vor Biopharma is somewhat reliable given 3 months investment horizon. Vor Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.17, which indicates the firm had a 0.17 % return per unit of risk over the last 3 months. We were able to break down and interpolate data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.4% are justified by taking the suggested risk. Use Vor Biopharma Coefficient Of Variation of 1110.64, risk adjusted performance of 0.0806, and Semi Deviation of 6.17 to evaluate company specific risk that cannot be diversified away. Vor Biopharma holds a performance score of 13 on a scale of zero to a hundred. The entity has a beta of 0.93, which indicates possible diversification benefits within a given portfolio. Vor Biopharma returns are very sensitive to returns on the market. As the market goes up or down, Vor Biopharma is expected to follow. Use Vor Biopharma sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on Vor Biopharma.
Auto-correlation | -0.19 |
Insignificant reverse predictability
Vor Biopharma has insignificant reverse predictability. Overlapping area represents the amount of predictability between Vor Biopharma time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vor Biopharma price movement. The serial correlation of -0.19 indicates that over 19.0% of current Vor Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.19 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 2.89 |
Pair Trading with Vor Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Vor Stock
Moving against Vor Stock
| 0.54 | DRMA | Dermata Therapeutics | PairCorr |
| 0.53 | OSE | OSE Pharma SA | PairCorr |
| 0.51 | ABNX | Abionyx Pharma SA | PairCorr |
| 0.41 | VCEL | Vericel Corp Ord | PairCorr |
| 0.37 | JUMP | Leveljump Healthcare Corp | PairCorr |
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.